Since BC therapeutic backbones include endocrine therapy, anti-HER2 therapy, and chemotherapy 25, we continued to evaluate the effect of SLC3A2 expression on above-mentioned therapeutic responses in clinical cancer cohorts. This evidence concerns the gene SLC3A2 and breast cancer.